Skip to main content

Advertisement

SpringerLink
Log in

Treatment for colorectal liver metastases: a review

  • Current Concepts in Clinical Surgery
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Introduction

Over the past decade, the emergence of surgical adjuncts such as portal vein embolization, two-stage hepatectomy, and ablative therapies not only decreases mortality and morbidity after an extended hepatectomy but also broadens the indication for surgical treatment of liver metastasis from colorectal cancer. Combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin, and targeted monochromal antibodies can downsize the tumor burden to the extent that formerly unresectable metastases can sometimes be excised.

Discussion

The 5-year survival rate following liver resection ranges between 25% and 58%. During the 5-fluorouracil/folinic acid with oxaliplatin and 5-fluorouracil/folinic acid with irinotecan treatment period, the patients who were deemed to be resectable should be considered as surgical candidates regardless of the associated adverse predictive factors. The emergence of epidermal growth factor receptor antibody agents, which act effectively in patients with Kras wild-type tumor, fosters treatment individualization.

Conclusion

The efficacy of the perioperative chemotherapy on survival benefit for resectable liver metastases has not been justified. However, the timing and indication of surgical treatment paradigm in colorectal liver metastasis, including for synchronous disease and extrahepatic disease, are dramatically changing with the development of chemotherapeutic agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rastogi T, Hildesheim A, Sinha R (2004) Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 4:909–917

    Article  CAS  PubMed  Google Scholar 

  2. Bovier AM, Remontet L, Jougla E (2004) Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 28:877–881

    Article  Google Scholar 

  3. Faivre J, Manfredi S, Bouvier AM (2003) Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 187:815–822

    PubMed  Google Scholar 

  4. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM (1984) The natural history of hepatic metastases from colorectal cancer. Ann Surg 199:502–508

    Article  CAS  PubMed  Google Scholar 

  5. Abdalla EK, Vanthey JN, Ellis LM, Ellis V, Pollock R, Bronglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825

    Article  PubMed  Google Scholar 

  6. Rougier P, Milan C, Lazorthes F (1995) Prospective study of prognostic factors in patients with unresected metastases from colorectal cancer. Br J Surg 82:1397–1400

    Article  CAS  PubMed  Google Scholar 

  7. de Gramont A, FIger A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Lovet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  8. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahorey MR, Dakhil SR Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II Study. J Clin Oncol 23:9243–9249

    Article  CAS  PubMed  Google Scholar 

  9. Benoist S, Pautrat K, Mitry E, Rougier R, Penna C, Nordinger B (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92:1155–1160

    Article  CAS  PubMed  Google Scholar 

  10. Poston GJ, Adam R, Curley S, Figueras J, Haller D, Kunilinger F, Mewtha G, Nordinger B, Patt Y, Premrose J, Roh M, Rougier P (2005) OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clinic Oncol 23:7125–7134

    Article  Google Scholar 

  11. Cunningham O, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  CAS  PubMed  Google Scholar 

  12. Hurwitz H, Fehrenbacha L, Norotomy W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  13. Nordinger B, Giuguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scorning system to improve case selection based on 1568 patients. Cancer 77:1254–1262

    Article  Google Scholar 

  14. Smith MD, Parks RW (2008) Prognostic models for predicting death after hepatectomy in individual with hepatic metastases from colorectal cancer. World J Surg 32:1108–1109

    Article  CAS  PubMed  Google Scholar 

  15. Arru M, Aldrighetti L, Casodi R, DiPoLo S, Orsenigo E, Stella M (2008) Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg 22:93–103

    Article  Google Scholar 

  16. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Iris W, Starzl TE (1994) Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery 116:703–711

    CAS  PubMed  Google Scholar 

  17. Tanaka K, Shimada H, Fujii Y, Endo I, Sekido H, Togo S, Ike H (2004) Prehepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver. Langenbeck Arch Surg 389:371–379

    Article  Google Scholar 

  18. Kanemitsu Y, Kato T (2008) Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg 32:1097–1107

    Article  PubMed  Google Scholar 

  19. Ree M, Tekkis PP, Welsch FKS et al (2008) Evaluation of long term survival after hepatic resection for metastatic colorectal cancer. A multifactorial model of 929 patients. Ann Surg 247:125–135

    Article  Google Scholar 

  20. Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963–969

    Article  CAS  PubMed  Google Scholar 

  21. Zakaria S, Donohue JH, Que FG et al (2007) Hepatic resection for colorectal metastases: value for risk scoring system? Ann Surg 246:183–191

    Article  PubMed  Google Scholar 

  22. Fong Y, Fortner J, Sun RL et al (1999) Clinical risk score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive case. Ann Surg 230:309–318

    Article  CAS  PubMed  Google Scholar 

  23. Small RM, Lubegky N, Shmueli E, Figer A, Aderka D, Nakache RK, Lausner JM, Ben-Haims M (2009) Response to chemotherapy predicts survival following resection of hepatio colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 99:93–98

    Article  PubMed  Google Scholar 

  24. Adam R, Pascal G, Cartaign D, Azoley D, Delvart V, Bernard Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contra indication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052–1064

    Article  PubMed  Google Scholar 

  25. Blatzer D, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 17:5299. doi:10:1200/JCO

    Google Scholar 

  26. Adam R, Whicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, Guettier C, Kunstinger F, Delvart V, Azouley D, Castaing D (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncology 26:1635–1641

    Article  Google Scholar 

  27. Tan MCB, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM (2009) Chemotherapy-induced normalization of PDG uptake by colorectal liver metastases does not normally indicate complete pathologic response. J Gastrointest Surg 11:1112–1119

    Article  Google Scholar 

  28. Bilchik AJ, Poston G, Adam R, Choti MA (2008) Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol 26:5320–5321

    Article  PubMed  Google Scholar 

  29. Van Custem E, Nordinger B, Adam R et al (2006) Towards a pan-European consumes on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221

    Article  Google Scholar 

  30. Poston GJ, Figueres J, Giuliante F, Nuzzo G, Sobrero AF, Gigot J-F, Nordinger B, Adam R, Graenberger T, Choti M, Bilckit AJ, Van Custem JD, Chiang JM, D’Angelica M (2008) Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 26:4828–4833

    Article  PubMed  Google Scholar 

  31. Tournigand C, Andre T, Acille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GEROR study. J Clin Oncol 22:229–237

    Article  CAS  PubMed  Google Scholar 

  32. Cals L, Rixe O, Francois E et al (2004) Dose-finding study of weekly 24 h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15:1018–1024

    Article  CAS  PubMed  Google Scholar 

  33. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 351:337–345

    Article  CAS  Google Scholar 

  34. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal center, Irinotecan Study Group. N Eng J Med 343:905–914

    Article  CAS  Google Scholar 

  35. Tabernero J, Van Custem E, Diaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225–5232

    Article  CAS  PubMed  Google Scholar 

  36. Saitz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractomy colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  CAS  Google Scholar 

  37. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522

    Article  CAS  PubMed  Google Scholar 

  38. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paul B, Kumstlinger F, Ghemard O, Levi F, Bismuth H (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657

    Article  PubMed  Google Scholar 

  39. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F (2001) Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal cancer. Ann Surg Oncol 8:347–353

    Article  CAS  PubMed  Google Scholar 

  40. Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456

    Article  CAS  PubMed  Google Scholar 

  41. Abad A, Massuti B, Anton A et al (2007) Colorectal cancer metastases resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluouracil: final results of a phase II study. Acta Oncol 47:286–292

    Article  CAS  Google Scholar 

  42. Barone C, Nuzzo G, Casseno A et al (2007) Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97:1035–1039

    Article  CAS  PubMed  Google Scholar 

  43. Kemeny NE, Huitzil Melendez FD, Capanu M, et al (2009) Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (in press). doi:10.1200/JCO.2008.20.1301

  44. Zelck L, Bugat R, Cherqui D et al (2003) Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer. Ann Oncol 14:1537–1542

    Article  Google Scholar 

  45. Adam R, Aloia T, Levin F, Wicherts DA, de Hans RJ, Paule B et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–4602

    Article  CAS  PubMed  Google Scholar 

  46. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumor response and resection rate. Ann Oncol 16:1311–1319

    Article  CAS  PubMed  Google Scholar 

  47. Capussotti L, Muratore A, Mulas MM, Massucco P, Agliatta M (2006) Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg 93:1001–1006

    Article  CAS  PubMed  Google Scholar 

  48. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovanni I, Barone C (2007) Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 11:318–324

    Article  PubMed  Google Scholar 

  49. Ducreux M, Ychou M, Laplanche A et al (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the federation national des centre de butte contre le cancer. J Clin Oncol 23:4881–4887

    Article  CAS  PubMed  Google Scholar 

  50. Mocellin S, Piloti P, Lise M, NiHi D (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25:5649–5654

    Article  PubMed  Google Scholar 

  51. Kerr D, McAdrede C, Ledermann J et al (2003) Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomized trial. Lancet 61:368–373

    Article  Google Scholar 

  52. Cohen A, Kemeny N (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8:553–566

    Article  PubMed  Google Scholar 

  53. Nordlinger B, Parc R, Delva E et al (1987) Hepatic resection for colorectal liver metastases. Ann Surg 205:256–263

    Article  CAS  PubMed  Google Scholar 

  54. Parks R, Gonen M, Kemeny N, Jarnagin W et al (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753–763

    Article  PubMed  Google Scholar 

  55. Adam R, Pascal G, Cartaizn D, Azoley D, Delvart V, Bernard Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contra indication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052–1064

    Article  PubMed  Google Scholar 

  56. Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963–969

    Article  CAS  PubMed  Google Scholar 

  57. Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939–3945

    Article  PubMed  Google Scholar 

  58. LeCouter J, Moritz DR, Li B et al (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR1. Science 299:890–893

    Article  CAS  PubMed  Google Scholar 

  59. Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850

    CAS  PubMed  Google Scholar 

  60. Tyagi P, Grothey A (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6:261–264

    Article  CAS  PubMed  Google Scholar 

  61. Gruenberger B, Tamandle D, Schuller J, Scheithauer W, Zielinsk C, Hebstand F, Grenberger T (2008) Bevacizumab, Capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26(11):1830–1835

    Article  CAS  PubMed  Google Scholar 

  62. Reddy KS, Horse AM, Hurwitz IH, Bendel CJ, Gan JT, Hill ET, Clary MB (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106

    Article  PubMed  Google Scholar 

  63. Van Custem E, Lang I, D’Laens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFILI or without cetuximab: the CRYSTAL experience. J Clin Oncol 26(Suppl):5s Abstr 2

    Google Scholar 

  64. Bokemeyer C, Bandarenko I, Mahkson A, Jartmann Jt (2009) Fluorouracil leucovorin and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  65. Fakih M (2008) Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Expert Rev Anticancer Ther 8:1471–1480

    Article  CAS  PubMed  Google Scholar 

  66. Nordlinger B (2008) Preoperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC 40983): a randomised controlled trial. Lancet 371:1007–1016

    Article  CAS  PubMed  Google Scholar 

  67. Pawlik TM, Olino K, Gleisner AL, Torbenson M et al (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868

    Article  PubMed  Google Scholar 

  68. Rubbia-Brandt L, Audard V, Roth SP, AD BC et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466

    Article  CAS  PubMed  Google Scholar 

  69. Fernandez FG, Ritter J, Goodwin JW, Linehan DC et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853

    Article  PubMed  Google Scholar 

  70. Nakano H, Oussultzoglou E, Rosso E, Casnedi S et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal metastases receiving preoperative chemotherapy. Ann Surg 247:118–124

    Article  PubMed  Google Scholar 

  71. Zorzi D, Laurent A, Pawlik TM, Laumes GY, Vauthey JN, Abdalla EK (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 97:274–286

    Article  CAS  Google Scholar 

  72. Washington K, Lane KL, Mayers WC (1993) Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 17:1151–1158

    Article  CAS  PubMed  Google Scholar 

  73. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90 days mortality after resection of hepatic colorectal metastases. J Clin Oncol 24:2065–2072

    Article  CAS  PubMed  Google Scholar 

  74. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983–4990

    Article  CAS  PubMed  Google Scholar 

  75. Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I et al (2008) Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery 143:259–270

    Article  PubMed  Google Scholar 

  76. Hughes KS, Rosenstain RB, Songhorabodi S et al (1988) Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dos Colon Rectum 31:1–4

    Article  CAS  Google Scholar 

  77. Sheele J, Stangle R, Altendorf-Hofmann A, Gall FP (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110:13–29

    Google Scholar 

  78. Sheele J, Stangle R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal metastases. World J Surg 19:59–71

    Article  Google Scholar 

  79. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766

    Article  PubMed  Google Scholar 

  80. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825

    Article  PubMed  Google Scholar 

  81. Fernandez FG, Dnebin JA, Linehan DC et al (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 FDG. Ann Surg 240:438–447

    Article  PubMed  Google Scholar 

  82. Pawlik TM, Scogins CR, Zorzi D, Abdalla EK et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722

    Article  PubMed  Google Scholar 

  83. Lorenz M, Muller HH, Sharmann H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluouracil and folinic acid for liver metastases of colorectal cancer German Cooperative on Liver Metastases. Ann Surg 228:756–762

    Article  CAS  PubMed  Google Scholar 

  84. Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA et al (2004) Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 239:722–730

    Article  PubMed  Google Scholar 

  85. Shoup M, Gonen MD, Angelica M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7:325–330

    Article  PubMed  Google Scholar 

  86. Akita H, Sasaki Y, Yamada T, Gotoh K, Ohigashi H et al (2008) Real-time intraoperative assessment of residual liver functional reserve using pulse Dye Densitometry. World J Surg 32:2668–2674

    Article  PubMed  Google Scholar 

  87. Abdalla EK, Hicks ME, Vauthey JN (2001) Portal vein embolization: rationale, technique and future prospects. Br J Surg 88:165–175

    Article  CAS  PubMed  Google Scholar 

  88. Tanaka K, Shimada H, Matsuo M, Ueda I, Endo I, Togo S (2007) Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. EJSO 33:329–335

    Article  CAS  PubMed  Google Scholar 

  89. Zacherl J, Scheuba C, Imhof M, Zacherl M et al (2002) Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg 26:550–554

    Article  PubMed  Google Scholar 

  90. Yasui K, Shimizu Y (2005) Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol 10:86–96

    Article  PubMed  Google Scholar 

  91. Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137:833–840

    Article  PubMed  Google Scholar 

  92. Finch RJB, Malik HZ, Hamady ZZR, Al-Mukhatar A et al (2007) Effect of type of resection on outcome of hepatic resection for colorectal metastases. Br J Surg 94:1242–1248

    Article  CAS  PubMed  Google Scholar 

  93. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andre A et al (2006) Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 10:86–94

    Article  PubMed  Google Scholar 

  94. Cady B, Jenkis RL, Steele GD, Lewis WD, Stone HD et al (1998) Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg 227:566–571

    Article  CAS  PubMed  Google Scholar 

  95. Are C, Gonen M, Zazzali K et al (2007) The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 246:295–300

    Article  PubMed  Google Scholar 

  96. Nuzzo G, Giuliante F, Ardio F, Vellone M, Giovanni I, Fiderico B, Vecchio FM (2008) Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: single-center experience. Surgery 143:384–393

    Article  PubMed  Google Scholar 

  97. Altendorf-Hofmann A, Sheele J (2003) A critical review of the major indicator of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 12:165–192

    Article  PubMed  Google Scholar 

  98. Weber JC, Nakano H, Bachellier P et al (2001) Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 182:81–88

    Article  CAS  PubMed  Google Scholar 

  99. Jonas S, Thelen A, Benckert C, Spinell A et al (2007) Extended resections of liver metastases from colorectal cancer. World J Surg 31:511–521

    Article  CAS  PubMed  Google Scholar 

  100. Yasui K, Hirai T, Kato T, Torii A et al (1997) A new macroscopic classification predicts prognosis for patients with liver metastases from colorectal cancer. Ann Surg 226:582–586

    Article  CAS  PubMed  Google Scholar 

  101. Jaeck D, Nakano H, Bachellier P, Inoue K et al (2002) Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 9:430–438

    Article  PubMed  Google Scholar 

  102. Adam R, Laurent A, Azouley D, Castaing D, Bismuth H (2000) Two stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232:777–785

    Article  CAS  PubMed  Google Scholar 

  103. Jaeck D, Oussoutzoglou E, Rosso E et al (2004) A two-stage hepatectomy procedure combined with PVE to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240:1037–1051

    Article  PubMed  Google Scholar 

  104. Dennis AW, Miller R, de Haas RJ et al (2008) Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248:994–1005

    Article  Google Scholar 

  105. Pamecha V, Nedjat-Shokouchi B, Burusamy K et al (2008) Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolization and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. Dig Surg 25:387–393

    Article  CAS  PubMed  Google Scholar 

  106. Pawlik TM, Izzo F, Cohen DS et al (2003) Combined resection and radio frequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10:1059–1069

    Article  PubMed  Google Scholar 

  107. El-gendi AM, Khorsandi SE, Pai M et al (2008) Repeat hepatic resection using a Rf-assisted technique. Dig Surg 25:293–299

    Article  PubMed  Google Scholar 

  108. Curley SA (2003) Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 10:338–347

    Article  PubMed  Google Scholar 

  109. Siperstein AE, Barber E, Ballem N, Parikh T (2007) Survival after radiofrequency ablation of colorectal liver metastases—10 year experience. Ann Surg 246:559–567

    Article  PubMed  Google Scholar 

  110. Bilchik AJ, Wood TF, Allegra DP (2001) Radiofrequency ablation of unresectable hepatic malignancies: lesson learned. Oncologist 6:24–33

    Article  CAS  PubMed  Google Scholar 

  111. Berber E, Tsinberg M, Tellioglu G et al (2008) Resection versus laparoscopic radio frequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12:1967–1972

    Article  PubMed  Google Scholar 

  112. Martin R, Paty P, Fong Y et al (2003) Simultaneous live and colorectal resections are safe for synchronous colorectal liver metastases. J Am Coll Surg 197:233–241

    Article  PubMed  Google Scholar 

  113. Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H (2004) Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 136:650–659

    Article  PubMed  Google Scholar 

  114. Capussotti L, Ferrero A, Vigano L et al (2007) Major liver resection synchronous with colorectal surgery. Ann Surg Oncol 14:195–201

    Article  PubMed  Google Scholar 

  115. Weber JC, Bachellier P, Oussoultzoglow E, Jaeck D (2003) Simultaneous resection of colorectal primary tumor and synchronous liver metastases. Br J Surg 90:956

    Article  CAS  PubMed  Google Scholar 

  116. Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946

    CAS  PubMed  Google Scholar 

  117. Elias D, Ouellet JF, Bellon N et al (2003) Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 90:567–574

    Article  CAS  PubMed  Google Scholar 

  118. Jaeck D, Oussoultzoglou E, Rosso E (2007) Hepatectomy for colorectal metastases in the presence of extrahepatic disease. Surg Oncol Clin N Am 16:507–523

    Article  PubMed  Google Scholar 

  119. Inoue M, Ohta M, Iuchi K et al (2004) Benefits of surgery for patients with pulmonary metastases from colorectal cancer. Ann Thorac Surg 78:238–244

    Article  PubMed  Google Scholar 

  120. Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary metastases. J Am Coll Surg 205:231–238

    Article  PubMed  Google Scholar 

  121. Adam R, Bismuth H, Castaing D et al (1997) Repeat hepatectomy for colorectal liver metastases. Ann Surg 225:51–60

    Article  CAS  PubMed  Google Scholar 

  122. Antonion A, Lovegrove RE, Tilney HS et al (2007) Meta analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery 141:9–18

    Article  Google Scholar 

  123. Minagawa M, Makuuchi M, Torzilli G et al (2000) Extension of the frontiers of surgical indication in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231:487–499

    Article  CAS  PubMed  Google Scholar 

  124. Douillard JY, Cumingham D, Roth AD et al (2000) Irinotecan combined with fluororacil compared with fluorouracil alone as first-live treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355:1041–1047

    Article  CAS  PubMed  Google Scholar 

  125. Goldberg RM, Sargent DJ, Morant RS et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  126. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E et al (2008) A tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFILINOX): a phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother Pharmacol 62:195–201

    Article  CAS  PubMed  Google Scholar 

  127. Quenet F, Nordinger B, Rivoire M (2004) Resection of previously unresectable liver metastases from colorectal cancer after chemotherapy CPT11/L-OHP/LV5FU (Fol firinox): a prospective II trial. Proc Am Soc Clin Oncol Abstr3613

  128. Hurwitz H, Fehrevbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  129. Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIR) as first-line treatment for metastatic colorectal cancer. J Clin Oncol 25:1670–1676

    Article  CAS  PubMed  Google Scholar 

  130. Okano Y, Yamamoto J, Kosuge T, Ymamamoto S, Sakamoto M, Nakanishi Y, Hirohashi S (2000) Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathological study of 152 first resection cases. Cancer 89:267–275

    Article  CAS  PubMed  Google Scholar 

  131. Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  CAS  PubMed  Google Scholar 

  132. Pozzo C, Basso M, Cassano A et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15:933–939

    Article  CAS  PubMed  Google Scholar 

  133. Van Custem E, Nowacki M, Long I et al (2007) Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-live treatment of patients with metastatic colorectal cancer the crystal trial. ASCO Annual Meeting, 2007; abst

Download references

Author information

Authors and Affiliations

  1. The Medical Division of the Head Office, Japan Labor Health and Welfare Organization, Kawasaki, Japan

    Hiroshi Shimada

  2. Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Kuniya Tanaka & Itaru Endou

  3. Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Yasushi Ichikawa

Authors
  1. Hiroshi Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kuniya Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Itaru Endou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Shimada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimada, H., Tanaka, K., Endou, I. et al. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg 394, 973–983 (2009). https://doi.org/10.1007/s00423-009-0530-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-009-0530-8

Keywords

Search

Navigation